Hepatic impairment: phase 1 pharmacokinetic study in mild and moderate impairment
Renal impairment: phase 1 pharmacokinetic study
Renal and hepatic laboratory exclusions in the ABTECT induction trials
Pregnancy, breastfeeding, and contraception in the ABTECT trials
Pregnancy: reports in ABTECT maintenance Part 1
Contraception for male participants: phase 1 study in healthy Japanese men
Older adults: participants aged 65 years or older in the ABTECT induction trials
“Among the 1272 randomized and treated pts in ABTECT trials, 1183 were <65 yo and 89 were ≥65 yo” (opens the source at this quote in a new tab)
“Among pts <65 yo, TEAEs occurred in 59.8%, 49.5%, and 50.3% of those receiving Obe-50, Obe-25, and PBO, respectively.” (opens the source at this quote in a new tab)
“For patients ≥65 yo, rates were 65.9%, 38.9%, and 55.6%.” (opens the source at this quote in a new tab)
“Headache was the most frequent TEAE when treated with Obe across all age groups.” (opens the source at this quote in a new tab)
“Rates of serious TEAEs and TEAEs leading to study drug discontinuation were similar between Obe and PBO.” (opens the source at this quote in a new tab)
“In both ABTECT induction trials, obefazimod demonstrated consistent efficacy and safety in the elderly population, with no new or unexpected safety findings.” (opens the source at this quote in a new tab)
Pediatric development: European paediatric investigation plan
Adolescents aged 16 to 17 years in the ABTECT induction trials
Pediatric minitablet formulation: relative bioavailability study in adults